J&J Natrecor “Dear Doctor” Letter Advises Against Outpatient Use
Executive Summary
Administration of Johnson & Johnson/Scios' Natrecor (nesiritide) in the outpatient setting is an "unsupported use" of the congestive heart failure therapy, the company said in a letter to health care practitioners
You may also be interested in...
FDA Approval Shouldn’t Be Based On Surrogate Endpoints – Natrecor Article
The ongoing debate surrounding the safety of Scios' congestive heart failure therapy Natrecor (nesiritide) suggests that FDA should not approve drugs based only on surrogate endpoints, an article published in the July/August 2006 issue of Health Affairs argues
FDA Approval Shouldn’t Be Based On Surrogate Endpoints – Natrecor Article
The ongoing debate surrounding the safety of Scios' congestive heart failure therapy Natrecor (nesiritide) suggests that FDA should not approve drugs based only on surrogate endpoints, an article published in the July/August 2006 issue of Health Affairs argues
Natrecor Recommended Use Initiative Differs Slightly From Panel Advice
Scios' new educational materials for Natrecor (nesiritide) will recommend use of the drug for hospitalized patients with either dyspnea at rest or minimal activity - a slight departure from advice offered by a panel of experts recently convened by the Johnson & Johnson subsidiary